role of “ischemia modified albumin” (ima) in acute coronary syndromes

Clicks: 201
ID: 183470
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #245 of 437 articles by views in renewable energy

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 437 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Background: Diagnosis of acute coronary syndrome (ACS) is important, due to the associated very high mortality. Failure to diagnose ACS is a problem both for the patients and the clinicians. Ischemia modified albumin (IMA) has already been licensed by the US Food and Drug Administration for the diagnosis of suspected myocardial ischemia. Methods: Patients attending the emergency department (ED) within 6 h after having features of ACS were selected. IMA was done on admission. Blinded to the IMA results patients were fully evaluated and a diagnosis of non-ischemic chest pain (NICP), unstable angina (UA) or myocardial infarction (MI) was made. Later IMA results were correlated in each group. Results: Mean IMA value was 56.38 ± 23.89 u/ml in NICP group whereas in UA group it was 89.00 ± 7.76 u/ml and MI group was 87.50 ± 9.62 u/ml. This showed a sensitivity of 92% and specificity of 87%. The positive predictive value of the test was 88% and negative predictive value was 94%. In 16 patients an early diagnosis could be made when compared with Trop-T. Of the 89 patients 11 patients died in hospital. The IMA value was compared between this group and the patients who survived. Patients who died had a mean IMA value of 88.5 with a standard deviation of 5.33 whereas in patients who survived the mean value was 78.26 which was not statistically significant. Conclusion: In conclusion the benefit of the test would be to rule out ACS in patients who present early to ED with inconclusive diagnosis.
Reference Key
reddy2014indianrole Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;C. Bhakthavatsala Reddy;Cijo Cyriac;Hrishikesh B. Desle
Journal renewable energy
Year 2014
DOI
10.1016/j.ihj.2014.12.005
URL
http://www.sciencedirect.com/science/article/pii/S0019483214007421
Keywords
acute coronary syndrome

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.